Xiangchen Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xiangchen Kong has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Xiaosong Ma
6 shared publicationsBingfeng Li
5 shared publicationsDan Yan
Shenzhen University Diabetes Institute, Shenzhen Key Laboratory of Metabolism and Cardiovascular Homeostasis, Shenzhen University Medical School, Shenzhen, China
4 shared publicationsSimian Lv
4 shared publicationsYing Ying
3 shared publicationsAnyi Hu
Shenzhen University Diabetes Institute, School of Medicine Shenzhen University China
2 shared publications
Latest Publications
- 23 September 2026
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 623
Impaired FXR-syntaxin 1A pathway contributes to diabetic β-cell secretory dysfunction
- 23 September 2026
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 623
Impaired FXR-syntaxin 1A pathway contributes to diabetic β-cell secretory dysfunction
- Open Access
- 15 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , e03072
Deficiency of SCAMP5 Triggers Pancreatic β‐Cell Secretory Dysfunction and Apoptosis
The late stage of type 2 diabetes is characterized by secretory dysfunction and increased β‐cell apoptosis, but the underlying mechanisms are not fully understood. The expression and function of secretory carrier membrane protein 5 (SCAMP5) in β‐cells are unclear. The aim is to explore the role of SCAMP5 in diabetic β‐cell failure. SCAMP5 expression is reduced in β‐cells under diabetic conditions. Notably, SCAMP5 deficiency diminishes insulin secretion, which is involved in reduced Ca V 1.2 expression. Additionally, decreased SCAMP5 triggers β‐cell apoptosis, suggesting the anti‐apoptotic role of SCAMP5 in β‐cells. Mechanistically, SCAMP5 downregulates the protein expression of voltage‐dependent anion channel (VDAC1) and interacts with it, thereby repressing VDAC1‐recruited Bax to mitochondria, thus inhibiting the release of cytochrome c from mitochondria to the cytoplasm, culminating in preventing β‐cell apoptosis. Furthermore, hyperglycemia‐activated carbohydrate‐responsive element‐binding protein (ChREBP) epigenetically represses SCAMP5 expression by reducing trimethylation of histone H3 at lysine 4 (H3K4me3) within the Scamp5 promoter. These findings highlight the essential role of the ChREBP‐controlled SCAMP5 in β‐cell insulin secretion and apoptosis, revealing a previously unrecognized mechanism underlying the β‐cell failure in diabetes.
- 15 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , e03072
Open AccessDeficiency of SCAMP5 Triggers Pancreatic β‐Cell Secretory Dysfunction and Apoptosis
The late stage of type 2 diabetes is characterized by secretory dysfunction and increased β‐cell apoptosis, but the underlying mechanisms are not fully understood. The expression and function of secretory carrier membrane protein 5 (SCAMP5) in β‐cells are unclear. The aim is to explore the role of SCAMP5 in diabetic β‐cell failure. SCAMP5 expression is reduced in β‐cells under diabetic conditions. Notably, SCAMP5 deficiency diminishes insulin secretion, which is involved in reduced Ca V 1.2 expression. Additionally, decreased SCAMP5 triggers β‐cell apoptosis, suggesting the anti‐apoptotic role of SCAMP5 in β‐cells. Mechanistically, SCAMP5 downregulates the protein expression of voltage‐dependent anion channel (VDAC1) and interacts with it, thereby repressing VDAC1‐recruited Bax to mitochondria, thus inhibiting the release of cytochrome c from mitochondria to the cytoplasm, culminating in preventing β‐cell apoptosis. Furthermore, hyperglycemia‐activated carbohydrate‐responsive element‐binding protein (ChREBP) epigenetically represses SCAMP5 expression by reducing trimethylation of histone H3 at lysine 4 (H3K4me3) within the Scamp5 promoter. These findings highlight the essential role of the ChREBP‐controlled SCAMP5 in β‐cell insulin secretion and apoptosis, revealing a previously unrecognized mechanism underlying the β‐cell failure in diabetes.
- Open Access
- 20 December 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (12) , 1-12
FXR-regulated COX6A2 triggers mitochondrial apoptosis of pancreatic β-cell in type 2 diabetes
Pancreatic β-cell apoptosis plays a crucial role in the development of type 2 diabetes. Cytochrome c oxidase subunit 6A2 (COX6A2) and Farnesoid X Receptor (FXR) have been identified in pancreatic β-cells, however, whether they are involved in β-cell apoptosis is unclear. Here, we sought to investigate the role of FXR-regulated COX6A2 in diabetic β-cell apoptosis. We found that COX6A2 expression was increased in islets from diabetic animals, whereas FXR expression was suppressed. Notably, overexpression of COX6A2 facilitated β-cell apoptosis, whereas its deficiency attenuated this process and ameliorates type 2 diabetes, suggesting a pro-apoptotic role of COX6A2 in β-cells. Mechanistically, increased COX6A2 interacted with and enhanced the expression of voltage-dependent anion channel 1 (VDAC1), thereby promoting the mitochondrial translocation of Bax, leading to the release of cytochrome c from the mitochondria to the cytoplasm and ultimately causing β-cell apoptosis. Moreover, FXR negatively regulated COX6A2 expression through the inhibition of histone acetyltransferase p300 occupancy, diminishing histone H3 acetylation at lysine 27 on the Cox6a2 promoter. Furthermore, the deficiency of FXR intensified β-cell apoptosis under diabetic situations. Thus, it is probable that in diabetogenic environments, reduced FXR expression contributes to enhanced COX6A2 expression, culminating in β-cell apoptosis. These findings emphasize the essential involvement of the FXR/p300 pathway-controlled COX6A2 in β-cell apoptosis, revealing a previously undiscovered mechanism underlying diabetic β-cell apoptosis.
- 20 December 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (12) , 1-12
Open AccessFXR-regulated COX6A2 triggers mitochondrial apoptosis of pancreatic β-cell in type 2 diabetes
Pancreatic β-cell apoptosis plays a crucial role in the development of type 2 diabetes. Cytochrome c oxidase subunit 6A2 (COX6A2) and Farnesoid X Receptor (FXR) have been identified in pancreatic β-cells, however, whether they are involved in β-cell apoptosis is unclear. Here, we sought to investigate the role of FXR-regulated COX6A2 in diabetic β-cell apoptosis. We found that COX6A2 expression was increased in islets from diabetic animals, whereas FXR expression was suppressed. Notably, overexpression of COX6A2 facilitated β-cell apoptosis, whereas its deficiency attenuated this process and ameliorates type 2 diabetes, suggesting a pro-apoptotic role of COX6A2 in β-cells. Mechanistically, increased COX6A2 interacted with and enhanced the expression of voltage-dependent anion channel 1 (VDAC1), thereby promoting the mitochondrial translocation of Bax, leading to the release of cytochrome c from the mitochondria to the cytoplasm and ultimately causing β-cell apoptosis. Moreover, FXR negatively regulated COX6A2 expression through the inhibition of histone acetyltransferase p300 occupancy, diminishing histone H3 acetylation at lysine 27 on the Cox6a2 promoter. Furthermore, the deficiency of FXR intensified β-cell apoptosis under diabetic situations. Thus, it is probable that in diabetogenic environments, reduced FXR expression contributes to enhanced COX6A2 expression, culminating in β-cell apoptosis. These findings emphasize the essential involvement of the FXR/p300 pathway-controlled COX6A2 in β-cell apoptosis, revealing a previously undiscovered mechanism underlying diabetic β-cell apoptosis.
- 15 November 2024
- Published by American Diabetes Association in Diabetes
- Vol. 74 (2) , 175-187
Increased COX6A2 Promotes Pancreatic β-Cell Apoptosis and Is Suppressed in Diabetic GK Rats After Roux-en-Y Gastric Bypass
Roux-en-Y gastric bypass (RYGB) has been shown to inhibit β-cell apoptosis, but the underlying mechanisms are not yet fully understood. Cytochrome c oxidase subunit 6A2 (COX6A2) is expressed in β-cells. Here, we investigated the role of COX6A2 in β-cell apoptosis, especially following RYGB. We found that RYGB significantly reduced β-cell apoptosis, accompanied by decreased COX6A2 expression in islets from diabetic Goto-Kakizaki (GK) rats. It is noteworthy that overexpression of COX6A2 promoted β-cell apoptosis, whereas COX6A2 deficiency suppressed it, suggesting the proapoptotic role of COX6A2 in β-cells. Mechanistically, increased COX6A2 interacted with and upregulated the expression of cyclophilin D (CypD), facilitating the release of cytochrome c from mitochondria to the cytoplasm, thereby promoting β-cell apoptosis. Furthermore, high glucose–activated carbohydrate-responsive element-binding protein (ChREBP) epigenetically regulated COX6A2 expression by recruiting histone acetyltransferase p300 to augment histone H3 acetylation at the Cox6a2 promoter, a process inhibited by glucagon-like peptide 1 (GLP-1) signaling. Given that RYGB enhances GLP-1 signaling, RYGB is likely to deactivate ChREBP by boosting GLP-1/cAMP-dependent protein kinase (PKA) signaling, thereby reducing COX6A2 expression in islets from GK rats. These findings highlight the crucial role of the GLP-1/PKA/ChREBP axis-controlled COX6A2 in β-cell apoptosis, revealing a previously unrecognized mechanism underlying the reduction in β-cell apoptosis induced by RYGB. Article Highlights: Cytochrome c oxidase subunit 6A2 (COX6A2) expression is increased in diabetic islets. Increased COX6A2 promotes β-cell apoptosis via modulation of cyclophilin D-mediated cytochrome c release from mitochondria to the cytoplasm. Carbohydrate-responsive element-binding protein epigenetically regulates COX6A2 expression in β-cells. Roux-en-Y gastric bypass reduces COX6A2 expression by regulating the glucagon-like peptide 1/cAMP-dependent protein kinase/carbohydrate-responsive element-binding protein signaling pathway.
- 15 November 2024
- Published by American Diabetes Association in Diabetes
- Vol. 74 (2) , 175-187
Increased COX6A2 Promotes Pancreatic β-Cell Apoptosis and Is Suppressed in Diabetic GK Rats After Roux-en-Y Gastric Bypass
Roux-en-Y gastric bypass (RYGB) has been shown to inhibit β-cell apoptosis, but the underlying mechanisms are not yet fully understood. Cytochrome c oxidase subunit 6A2 (COX6A2) is expressed in β-cells. Here, we investigated the role of COX6A2 in β-cell apoptosis, especially following RYGB. We found that RYGB significantly reduced β-cell apoptosis, accompanied by decreased COX6A2 expression in islets from diabetic Goto-Kakizaki (GK) rats. It is noteworthy that overexpression of COX6A2 promoted β-cell apoptosis, whereas COX6A2 deficiency suppressed it, suggesting the proapoptotic role of COX6A2 in β-cells. Mechanistically, increased COX6A2 interacted with and upregulated the expression of cyclophilin D (CypD), facilitating the release of cytochrome c from mitochondria to the cytoplasm, thereby promoting β-cell apoptosis. Furthermore, high glucose–activated carbohydrate-responsive element-binding protein (ChREBP) epigenetically regulated COX6A2 expression by recruiting histone acetyltransferase p300 to augment histone H3 acetylation at the Cox6a2 promoter, a process inhibited by glucagon-like peptide 1 (GLP-1) signaling. Given that RYGB enhances GLP-1 signaling, RYGB is likely to deactivate ChREBP by boosting GLP-1/cAMP-dependent protein kinase (PKA) signaling, thereby reducing COX6A2 expression in islets from GK rats. These findings highlight the crucial role of the GLP-1/PKA/ChREBP axis-controlled COX6A2 in β-cell apoptosis, revealing a previously unrecognized mechanism underlying the reduction in β-cell apoptosis induced by RYGB. Article Highlights: Cytochrome c oxidase subunit 6A2 (COX6A2) expression is increased in diabetic islets. Increased COX6A2 promotes β-cell apoptosis via modulation of cyclophilin D-mediated cytochrome c release from mitochondria to the cytoplasm. Carbohydrate-responsive element-binding protein epigenetically regulates COX6A2 expression in β-cells. Roux-en-Y gastric bypass reduces COX6A2 expression by regulating the glucagon-like peptide 1/cAMP-dependent protein kinase/carbohydrate-responsive element-binding protein signaling pathway.
- Open Access
- 19 September 2024
- Published by Wiley in FEBS Open Bio
- Vol. 14 (11) , 1864-1872
Carbohydrate response element‐binding protein (ChREBP) mediates decreased SNAP25 expression in islets from diabetic Goto‐Kakizaki (GK) rats
SNAP25 plays an essential role in the glucose‐stimulated insulin secretion (GSIS) of pancreatic β‐cells. Carbohydrate response element‐binding protein (ChREBP) is an important transcription factor in β‐cells and, in this study, we aimed to explore whether ChREBP regulates SNAP25 expression in β‐cells. We show that diabetic Goto‐Kakizaki (GK) rats exhibited impaired insulin secretion and hyperglycemia, along with decreased SNAP25 expression and ChREBP phosphorylation in islets. SNAP25 knockdown decreased GSIS in β‐cells, while SNAP25 overexpression increased GSIS in β‐cells. Activation or overexpression of ChREBP led to reduced SNAP25 expression and subsequent suppression of GSIS. Conversely, ChREBP knockdown mitigated the reduction in SNAP25 expression caused by high glucose. Mechanistically, the activation of ChREBP by high glucose increased its occupancy and decreased the level of H3K4me3 at the Snap25 promoter. Our findings reveal the novel regulatory mechanisms of SNAP25 expression in β‐cells and suggest that SNAP25 may be involved in the regulation of β‐cell secretory function controlled by ChREBP.
- 19 September 2024
- Published by Wiley in FEBS Open Bio
- Vol. 14 (11) , 1864-1872
Open AccessCarbohydrate response element‐binding protein (ChREBP) mediates decreased SNAP25 expression in islets from diabetic Goto‐Kakizaki (GK) rats
SNAP25 plays an essential role in the glucose‐stimulated insulin secretion (GSIS) of pancreatic β‐cells. Carbohydrate response element‐binding protein (ChREBP) is an important transcription factor in β‐cells and, in this study, we aimed to explore whether ChREBP regulates SNAP25 expression in β‐cells. We show that diabetic Goto‐Kakizaki (GK) rats exhibited impaired insulin secretion and hyperglycemia, along with decreased SNAP25 expression and ChREBP phosphorylation in islets. SNAP25 knockdown decreased GSIS in β‐cells, while SNAP25 overexpression increased GSIS in β‐cells. Activation or overexpression of ChREBP led to reduced SNAP25 expression and subsequent suppression of GSIS. Conversely, ChREBP knockdown mitigated the reduction in SNAP25 expression caused by high glucose. Mechanistically, the activation of ChREBP by high glucose increased its occupancy and decreased the level of H3K4me3 at the Snap25 promoter. Our findings reveal the novel regulatory mechanisms of SNAP25 expression in β‐cells and suggest that SNAP25 may be involved in the regulation of β‐cell secretory function controlled by ChREBP.
- Open Access
- 12 August 2024
- Published by Springer Nature in Research Square
WITHDRAWN: FXR-regulated COX6A2 triggers mitochondrial apoptosis of pancreatic β-cell in type 2 diabetes
The full text of this preprint has been withdrawn by the authors due to author disagreement with the posting of the preprint. Therefore, the authors do not wish this work to be cited as a reference. Questions should be directed to the corresponding author.
- 12 August 2024
- Published by Springer Nature in Research Square
Open AccessWITHDRAWN: FXR-regulated COX6A2 triggers mitochondrial apoptosis of pancreatic β-cell in type 2 diabetes
The full text of this preprint has been withdrawn by the authors due to author disagreement with the posting of the preprint. Therefore, the authors do not wish this work to be cited as a reference. Questions should be directed to the corresponding author.
- 16 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-9
GLP-1 signaling-regulated SNAP25 is involved in improved insulin secretion in diabetic GK rats after Roux-en-Y gastric bypass surgery
Roux-en-Y gastric bypass surgery (RYGB) improves glucose-stimulated insulin secretion (GSIS) in type 2 diabetes (T2D) patients. SNAP25 plays an essential r
- 16 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-9
GLP-1 signaling-regulated SNAP25 is involved in improved insulin secretion in diabetic GK rats after Roux-en-Y gastric bypass surgery
Roux-en-Y gastric bypass surgery (RYGB) improves glucose-stimulated insulin secretion (GSIS) in type 2 diabetes (T2D) patients. SNAP25 plays an essential r
- Open Access
- 21 February 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (6)
FXR‐mediated epigenetic regulation of GLP‐1R expression contributes to enhanced incretin effect in diabetes after RYGB
In this study, we investigated how Roux‐en‐Y gastric bypass (RYGB) enhances glucagon‐like peptide 1 (GLP‐1) response in GK rats and explored the potential link between RYGB‐stimulated BAs/FXR signalling and GLP‐1R‐linked signalling in β‐cells, a key pathway that regulates glucose‐stimulated insulin secretion (GSIS). Here we show that RYGB restores GLP‐1R expression in GK rat islets. This involves increased total BAs as well as chenodeoxycholic acid (CDCA), leading to FXR activation, increasing FXR binding to the promoter of Glp‐1r and enhancing occupancy of histone acetyltransferase steroid receptor coactivator‐1 (SRC1), thus increasing histone H3 acetylation at the promoter. These coordinated events bring about increased GLP‐1R expression, resulting in greater GLP‐1 response in β‐cells. Moreover, ablation of FXR suppressed the stimulatory effects of GLP‐1. Thus, this study unravels the crucial role of the BAs/FXR/SRC1 axis‐controlled GLP‐1R expression in β‐cells, which results in enhanced incretin effect and normalized blood glucose of GK rats after RYGB.
- 21 February 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (6)
Open AccessFXR‐mediated epigenetic regulation of GLP‐1R expression contributes to enhanced incretin effect in diabetes after RYGB
In this study, we investigated how Roux‐en‐Y gastric bypass (RYGB) enhances glucagon‐like peptide 1 (GLP‐1) response in GK rats and explored the potential link between RYGB‐stimulated BAs/FXR signalling and GLP‐1R‐linked signalling in β‐cells, a key pathway that regulates glucose‐stimulated insulin secretion (GSIS). Here we show that RYGB restores GLP‐1R expression in GK rat islets. This involves increased total BAs as well as chenodeoxycholic acid (CDCA), leading to FXR activation, increasing FXR binding to the promoter of Glp‐1r and enhancing occupancy of histone acetyltransferase steroid receptor coactivator‐1 (SRC1), thus increasing histone H3 acetylation at the promoter. These coordinated events bring about increased GLP‐1R expression, resulting in greater GLP‐1 response in β‐cells. Moreover, ablation of FXR suppressed the stimulatory effects of GLP‐1. Thus, this study unravels the crucial role of the BAs/FXR/SRC1 axis‐controlled GLP‐1R expression in β‐cells, which results in enhanced incretin effect and normalized blood glucose of GK rats after RYGB.
- Open Access
- 14 August 2019
- Published by Wiley in Journal of Diabetes Research
- Vol. 2019, 1-9
FXR Mediates Adenylyl Cyclase 8 Expression in Pancreatic β-Cells
Adenylyl cyclase 8 (ADCY8) and Farnesoid X Receptor (FXR) have been identified in pancreatic β-cells and play important roles in insulin secretion. But the mechanisms underlying with respect to the regulation of ADCY8 expression in β-cells, particularly whether FXR is involved, remain unexplored. We now show that ADCY8 expression is decreased in Goto-Kakizaki (GK) rat islets compared with healthy Wistar controls. We also found that reduced ADCY8 is associated with decreased expression of FXR. Consistently, ADCY8 expression was suppressed by the knockdown of FXR in INS-1 832/13 cells, as well as the islets from FXR knockout mice. On the contrary, ADCY8 expression was increased in FXR-overexpressed INS-1 832/13 cells or in the case of FXR activation. Mechanistically, FXR directly binds to Adcy8 promoter and recruits the histone acetyltransferase Steroid Receptor Coactivator 1 (SRC1), thereby resulting in the increased acetylation of histone H3 in Adcy8 locus, promoting Adcy8 gene transcription in β-cells. Thus, this study indicates that FXR is a critical transcription factor that mediates ADCY8 expression in pancreatic β-cells and has characterized the chromatin modification associated with Adcy8 transcription.
- 14 August 2019
- Published by Wiley in Journal of Diabetes Research
- Vol. 2019, 1-9
Open AccessFXR Mediates Adenylyl Cyclase 8 Expression in Pancreatic β-Cells
Adenylyl cyclase 8 (ADCY8) and Farnesoid X Receptor (FXR) have been identified in pancreatic β-cells and play important roles in insulin secretion. But the mechanisms underlying with respect to the regulation of ADCY8 expression in β-cells, particularly whether FXR is involved, remain unexplored. We now show that ADCY8 expression is decreased in Goto-Kakizaki (GK) rat islets compared with healthy Wistar controls. We also found that reduced ADCY8 is associated with decreased expression of FXR. Consistently, ADCY8 expression was suppressed by the knockdown of FXR in INS-1 832/13 cells, as well as the islets from FXR knockout mice. On the contrary, ADCY8 expression was increased in FXR-overexpressed INS-1 832/13 cells or in the case of FXR activation. Mechanistically, FXR directly binds to Adcy8 promoter and recruits the histone acetyltransferase Steroid Receptor Coactivator 1 (SRC1), thereby resulting in the increased acetylation of histone H3 in Adcy8 locus, promoting Adcy8 gene transcription in β-cells. Thus, this study indicates that FXR is a critical transcription factor that mediates ADCY8 expression in pancreatic β-cells and has characterized the chromatin modification associated with Adcy8 transcription.
- Open Access
- 21 February 2019
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 218 (3) , 855-870
GLP-1 signaling suppresses menin’s transcriptional block by phosphorylation in β cells
Both menin and glucagon-like peptide 1 (GLP-1) pathways play central yet opposing role in regulating β cell function, with menin suppressing, and GLP-1 promoting, β cell function. However, little is known as to whether or how GLP-1 pathway represses menin function. Here, we show that GLP-1 signaling–activated protein kinase A (PKA) directly phosphorylates menin at the serine 487 residue, relieving menin-mediated suppression of insulin expression and cell proliferation. Mechanistically, Ser487-phosphorylated menin gains increased binding affinity to nuclear actin/myosin IIa proteins and gets sequestrated from the Ins1 promoter. This event leads to reduced binding of repressive epigenetic histone modifiers suppressor variegation 3–9 homologue protein 1 (SUV39H1) and histone deacetylases 1 (HDAC1) at the locus and subsequently increased Ins1 gene transcription. Ser487 phosphorylation of menin also increases expression of proproliferative cyclin D2 and β cell proliferation. Our results have uncovered a previously unappreciated physiological link in which GLP-1 signaling suppresses menin function through phosphorylation-triggered and actin/myosin cytoskeletal protein–mediated derepression of gene transcription.
- 21 February 2019
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 218 (3) , 855-870
Open AccessGLP-1 signaling suppresses menin’s transcriptional block by phosphorylation in β cells
Both menin and glucagon-like peptide 1 (GLP-1) pathways play central yet opposing role in regulating β cell function, with menin suppressing, and GLP-1 promoting, β cell function. However, little is known as to whether or how GLP-1 pathway represses menin function. Here, we show that GLP-1 signaling–activated protein kinase A (PKA) directly phosphorylates menin at the serine 487 residue, relieving menin-mediated suppression of insulin expression and cell proliferation. Mechanistically, Ser487-phosphorylated menin gains increased binding affinity to nuclear actin/myosin IIa proteins and gets sequestrated from the Ins1 promoter. This event leads to reduced binding of repressive epigenetic histone modifiers suppressor variegation 3–9 homologue protein 1 (SUV39H1) and histone deacetylases 1 (HDAC1) at the locus and subsequently increased Ins1 gene transcription. Ser487 phosphorylation of menin also increases expression of proproliferative cyclin D2 and β cell proliferation. Our results have uncovered a previously unappreciated physiological link in which GLP-1 signaling suppresses menin function through phosphorylation-triggered and actin/myosin cytoskeletal protein–mediated derepression of gene transcription.